ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0795

Corticosteroid Treatment in a Case of COVID-19-Associated Collapsing FSGS

Session Information

Category: Trainee Case Report

  • 000 Coronavirus (COVID-19)

Authors

  • Zemke, Anna M., Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, United States
  • Baxi, Pravir V., Division of Nephrology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, United States
  • Rodby, Roger A., Division of Nephrology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, United States
Introduction

Collapsing FSGS (cFSGS) is associated with viral infections including HIV, parvovirus B19 and CMV. Recent reports describe cFSGS in patients infected with coronavirus (COVID-19). While reports on idiopathic cFSGS suggest early institution of steroids improves renal outcomes, there are little data to guide treatment of cFSGS associated with infection. We present a case of AKI with severe abrupt nephrotic syndrome in a COVID-19 patient with cFSGS on biopsy and a rapid response to steroids.

Case Description

A 51 y/o black woman with no known medical history presented with 8 days of fever and SOB. COVID-19 testing was positive. Admission serum creatinine (sCr) was 3.2 mg/dL with an albumin of 2.6 g/dL. A urinalysis showed moderate blood and 3+ protein on dipstick along with granular casts. A urine albumin:Cr (UAC) ratio was 0.19 g/g. Despite volume resuscitation, her sCr continued to rise.

Workup included negative HIV, hepatitis panel, and parvovirus B19. ANA, ANCA, anti-dsDNA, C3, and C4 were neg/nl. On day 5, she was afebrile with resolution of her symptoms, but sCr was further elevated at 5.3 mg/dL and albumin was 1.1 g/dL. Repeat UAC ratio was elevated over lab measurable range. A biopsy showed cFSGS and ATN. She was started on 60mg of prednisone/day. Two weeks later, her sCr was 2.9 mg/dL, albumin 2.4 g/dL and her UAC ratio was 3.0 g/g (Fig 1).

Discussion

The optimal treatment for viral related cFSGS is unknown. Because diffuse foot process effacement typically accompanies this lesion, it is tempting to give steroids. However, there is concern that this may exacerbate the infection, and cFSGS may improve along with clearance of the virus. Still, steroids may hasten recovery and reduce morbidity associated with the nephrotic syndrome. The rapid improvement in proteinuria despite an increase in GFR suggests that steroids played a role in the recovery. A randomized trial would be necessary to determine the safety and efficacy of steroids for COVID-19 related cFSGS.

(Left) Jones stain highlighting collapse of glomerular tuft. Arrow pointing to the proliferation of visceral epithelial cells. (Right) Lab values: Admission to 2 weeks post discharge.